-
Je něco špatně v tomto záznamu ?
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
M. Pfirrmann, RE. Clark, W. Prejzner, M. Lauseker, M. Baccarani, S. Saussele, F. Guilhot, S. Heibl, R. Hehlmann, E. Faber, A. Turkina, G. Ossenkoppele, M. Höglund, A. Zaritskey, L. Griskevicius, U. Olsson-Strömberg, H. Everaus, P. Koskenvesa, B....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 1997-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
- MeSH
- chronická myeloidní leukemie farmakoterapie mortalita MeSH
- dospělí MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- pravděpodobnost MeSH
- prognóza MeSH
- registrace MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.
Abteilung für Innere Medizin 4 Klinikum Wels Grieskirchen Wels Austria
Almazov Medical Reseach Centre Institute of Oncology and Hematology St Petersburg Russian Federation
Clinical Investigation Centre INSERM CIC 1402 CHU Poitiers Poitiers France
Department of Hematology Jagiellonian Unversity Medical College Kraków Poland
Department of Hematology University Medical Centre Ljubljana Slovenia
Department of Hematology VU University Medical Center Amsterdam Netherlands
Department of Molecular and Clinical Cancer Medicine University of Liverpool Liverpool UK
Hematology Department Hospital Clinic IDIBAPS Barcelona Spain
Institute of Clinical Medicine Vilnius University Vilnius Lithuania
Institution of Medical Sciences University of Uppsala Uppsala Sweden
Klinik für Innere Medizin 2 Universitätsklinikum Jena Jena Germany
Medical University of Gdansk Gdansk Poland
Romanian Academy of Medical Sciences and Medical University Bucharest Romania
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027979
- 003
- CZ-PrNML
- 005
- 20210114152729.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-020-0931-9 $2 doi
- 035 __
- $a (PubMed)32601376
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pfirrmann, Markus $u Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie - IBE, Ludwig-Maximilians Universität, Munich, Germany. pfi@ibe.med.uni-muenchen.de.
- 245 14
- $a The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia / $c M. Pfirrmann, RE. Clark, W. Prejzner, M. Lauseker, M. Baccarani, S. Saussele, F. Guilhot, S. Heibl, R. Hehlmann, E. Faber, A. Turkina, G. Ossenkoppele, M. Höglund, A. Zaritskey, L. Griskevicius, U. Olsson-Strömberg, H. Everaus, P. Koskenvesa, B. Labar, T. Sacha, D. Zackova, F. Cervantes, A. Colita, I. Zupan, A. Bogdanovic, F. Castagnetti, J. Guilhot, J. Hasford, A. Hochhaus, VS. Hoffmann,
- 520 9_
- $a Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická myeloidní leukemie $x farmakoterapie $x mortalita $7 D015464
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pravděpodobnost $7 D011336
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Clark, Richard E $u Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
- 700 1_
- $a Prejzner, Witold $u Medical University of Gdansk, Gdansk, Poland.
- 700 1_
- $a Lauseker, Michael $u Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie - IBE, Ludwig-Maximilians Universität, Munich, Germany.
- 700 1_
- $a Baccarani, Michele $u Clinical Department of Hematology and Oncology L. and A. Seragnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
- 700 1_
- $a Saussele, Susanne $u III. Medizinische Klinik, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
- 700 1_
- $a Guilhot, François $u Clinical Investigation Centre, INSERM CIC 1402, CHU Poitiers, Poitiers, France.
- 700 1_
- $a Heibl, Sonja $u Abteilung für Innere Medizin IV, Klinikum Wels-Grieskirchen, Wels, Austria.
- 700 1_
- $a Hehlmann, Rüdiger $u III. Medizinische Klinik, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany. ELN Foundation, Weinheim, Germany.
- 700 1_
- $a Faber, Edgar $u Department of Hemato-Oncology, Faculty Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Turkina, Anna $u National Research Center for Hematology, Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation.
- 700 1_
- $a Ossenkoppele, Gert $u Department of Hematology, VU University Medical Center, Amsterdam, Netherlands.
- 700 1_
- $a Höglund, Martin $u Institution of Medical Sciences, University of Uppsala, Uppsala, Sweden.
- 700 1_
- $a Zaritskey, Andrey $u Almazov Medical Reseach Centre, Institute of Oncology and Hematology, St Petersburg, Russian Federation.
- 700 1_
- $a Griskevicius, Laimonas $u Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.
- 700 1_
- $a Olsson-Strömberg, Ulla $u Department of Medical Sciences, University of Uppsala and Section of Hematology, Uppsala University Hospital, Uppsala, Sweden.
- 700 1_
- $a Everaus, Hele $u Tartu University Hospital, Tartu, Estonia.
- 700 1_
- $a Koskenvesa, Perttu $u Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
- 700 1_
- $a Labar, Boris $u School of Medicine, University of Zagreb, Zagreb, Croatia.
- 700 1_
- $a Sacha, Tomasz $u Department of Hematology, Jagiellonian Unversity Medical College, Kraków, Poland.
- 700 1_
- $a Zackova, Daniela $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Cervantes, Francisco $u Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain.
- 700 1_
- $a Colita, Adriana $u Romanian Academy of Medical Sciences and Medical University, Bucharest, Romania.
- 700 1_
- $a Zupan, Irena $u Department of Hematology, University Medical Centre, Ljubljana, Slovenia.
- 700 1_
- $a Bogdanovic, Andrija $u Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Castagnetti, Fausto $u Clinical Department of Hematology and Oncology L. and A. Seragnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
- 700 1_
- $a Guilhot, Joëlle $u Clinical Investigation Centre, INSERM CIC 1402, CHU Poitiers, Poitiers, France.
- 700 1_
- $a Hasford, Joerg $u Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie - IBE, Ludwig-Maximilians Universität, Munich, Germany.
- 700 1_
- $a Hochhaus, Andreas $u Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
- 700 1_
- $a Hoffmann, Verena S $u Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie - IBE, Ludwig-Maximilians Universität, Munich, Germany.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 34, č. 8 (2020), s. 2138-2149
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32601376 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152727 $b ABA008
- 999 __
- $a ok $b bmc $g 1608314 $s 1119159
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 34 $c 8 $d 2138-2149 $e 20200629 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20210105
